Fresenius Kabi Unveils 2026 Strategy With Focus On Business Not Region
Increased Focus On Biosimilars And Peptides Under New CEO Michael Sen
Fresenius Kabi has revealed a five-year strategic roadmap, driven by its fresh management team, including broadly to increase the injectables specialist’s global competitiveness and advance organizational effectiveness.
You may also be interested in...
Fresenius Kabi And Formycon Ally On Stelara Rival
Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.
Kabi ‘Overdelivering’ On Saving Plans But Feels The Sting Of Inflation
Newly instated Fresenius group CEO Michael Sen took charge of his first earnings call following his appointment on 1 October, pushing the message of Kabi managing its own destiny amid a series of macroeconomic challenges.
Fresenius Delivers First US Biosimilar Approval
Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.